DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The "Bladder Cancer - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering. Bladder Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 52, 55, 1, 67, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 7, 3, 1, 12 and 3 molecules, respectively. Companies Mentioned

4SC AG Abivax SA Adaptimmune Therapeutics Plc Alligator Bioscience AB Altor BioScience Corp Amgen Inc AndroScience Corp Archivel Farma SL Array BioPharma Inc Asana BioSciences LLC Asieris Pharmaceuticals Co Ltd Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc Bavarian Nordic A/S Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Co CBT Pharmaceuticals Inc Celgene Corp Eisai Co Ltd Eli Lilly and Co F. Hoffmann-La Roche Ltd GlaxoSmithKline Plc Johnson & Johnson Merck & Co Inc Merck KGaA Novartis AG Ono Pharmaceutical Co Ltd Pfizer Inc Sanofi Seattle Genetics Inc Sierra Oncology Inc Vault Pharma Inc Vyriad Inc

Key Topics Covered

Introduction Bladder Cancer - Overview Bladder Cancer - Therapeutics Development Bladder Cancer - Therapeutics Assessment Bladder Cancer - Companies Involved in Therapeutics Development Bladder Cancer - Drug Profiles Bladder Cancer - Dormant Projects Bladder Cancer - Discontinued Products Bladder Cancer - Product Development Milestones Appendix

For more information about this report visit https://www.researchandmarkets.com/research/k5ck8s/bladder_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180612005729/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Bladder Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/12/2018 06:29 AM/DISC: 06/12/2018 06:28 AM

http://www.businesswire.com/news/home/20180612005729/en